Details for Patent: 10,421,729
✉ Email this page to a colleague
Which drugs does patent 10,421,729 protect, and when does it expire?
Patent 10,421,729 protects TYVASO DPI and is included in one NDA.
This patent has thirty-seven patent family members in thirteen countries.
Summary for Patent: 10,421,729
| Title: | Microcrystalline diketopiperazine compositions and methods |
| Abstract: | Disclosed herein are DKP microcrystals made by an improved method where they do not irreversibly self-assemble into microparticles. The microcrystals can be dispersed by atomization and re-formed by spray drying into particles having spherical shell morphology. Active agents and excipients can be incorporated into the particles by spray drying a solution containing the components to be incorporated into microcrystalline diketopiperazine particles. In particular, the microcrystalline particle compositions are suitable for pulmonary drug delivery of one or more peptides, proteins, nucleic acids and/or small organic molecules. |
| Inventor(s): | Wilson; Bryan R. (Brewster, NY), Guarneri; Joseph J. (Stamford, CT), Grant; Marshall L. (Newtown, CT) |
| Assignee: | MannKind Corporation (Westlake Village, CA) |
| Application Number: | 14/774,311 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; Device; |
Drugs Protected by US Patent 10,421,729
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United Therap | TYVASO DPI | treprostinil | POWDER;INHALATION | 214324-001 | May 23, 2022 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| United Therap | TYVASO DPI | treprostinil | POWDER;INHALATION | 214324-002 | May 23, 2022 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| United Therap | TYVASO DPI | treprostinil | POWDER;INHALATION | 214324-003 | May 23, 2022 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| United Therap | TYVASO DPI | treprostinil | POWDER;INHALATION | 214324-004 | May 23, 2022 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 10,421,729
| PCT Information | |||
| PCT Filed | March 14, 2014 | PCT Application Number: | PCT/US2014/029491 |
| PCT Publication Date: | September 18, 2014 | PCT Publication Number: | WO2014/144895 |
International Family Members for US Patent 10,421,729
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2014228415 | ⤷ Try a Trial | |||
| Australia | 2018253545 | ⤷ Try a Trial | |||
| Australia | 2020200744 | ⤷ Try a Trial | |||
| Australia | 2021203201 | ⤷ Try a Trial | |||
| Australia | 2022235510 | ⤷ Try a Trial | |||
| Australia | 2023282272 | ⤷ Try a Trial | |||
| Brazil | 112015023168 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
